Fundraising Fox
/Companies
Sign in

Sift Biosciences

San Carlos, US · Founded 2023 · 7 known investors

Find your way into Sift Biosciences

Sign up to see every warm intro you have to Sift Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Sift Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells. Its SIFT platform supports pipelines in oncology and autoimmunity, with the latter partnered with a large pharmaceutical company.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Sift Biosciences was founded in 2023 by Yue Clare Lou.

YCYue Clare Lou
Yue Clare LouCo-Founder & CEO30 Under 30 2025

Board

KBKevin Barrett
Kevin BarrettBoard directorManaging Partner at FREEFLOW
AM
Altar MunisBoard director

Investors · 7

SBI Holdings✓ confirmed by Sift BiosciencesTokyo

How we know: the company's own site · funding news · prnewswire.com · Not right? Tell us

Fifty Yearslisted by Fifty YearsSan Francisco · $250K – $2M

How we know: Fifty Years's portfolio page · Not right? Tell us

FREEFLOWlisted by FREEFLOWBerkeley
Lifespan Vision Ventureslisted by Lifespan Vision VenturesNorwalk

How we know: Lifespan Vision Ventures's portfolio page · prnewswire.com · Not right? Tell us

Also in the syndicate · 2

Freeflow VenturesleadValuence Ventures

Reported raises · per SEC filings

Form D private placements

$3.8M disclosed across 1 round · 2025

▶$3.8MraisedDec 2025 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin BarrettDirector
  • Altar MunisDirector
  • Yue LouExecutive Officer, Director
Offering amount
$3.8M
Amount sold
$3.8M
First sale
Nov 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Shift BioscienceShift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis. The company works in the aging and longevity biotech field, having discovered novel aging targets linked to disease states.
Life BiosciencesLife Biosciences is a biopharmaceutical company developing therapies focused on aging and age-related diseases, working across gene therapy and neuroscience programs. It advances drug candidates from discovery through clinical development.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Faeth TherapeuticsFaeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, PIKTOR, is an all-oral combination targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial and HR+/HER2- breast cancer.

Companies working in the same space as Sift Biosciences.

In the news

Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-generation T-cell Immunotherapy Platform - BioSpacebiospace.com · Feb 2026Sift Biosciences Raises $3.7M in Pre-Seed Fundingfinsmes.com · Feb 2026

Frequently asked questions

What does Sift Biosciences do?
Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells. Its SIFT platform supports pipelines in oncology and autoimmunity, with the latter partnered with a large pharmaceutical company.
Who founded Sift Biosciences?
Sift Biosciences was founded by Yue Clare Lou in 2023.
Who are Sift Biosciences's investors?
Sift Biosciences's investors include Eisai Innovation, Inc., SBI Holdings, Fifty Years, FREEFLOW, Lifespan Vision Ventures.
How much funding has Sift Biosciences raised?
Sift Biosciences has disclosed $3.8M raised across 1 round.
Where is Sift Biosciences headquartered?
Sift Biosciences is headquartered in San Carlos, US.